Tags

Type your tag names separated by a space and hit enter

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.

Abstract

Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    EpiConcept, Paris, France. e.kissling@epiconcept.fr

    , , , , , , , , , , , , , , , , , , ,

    Source

    MeSH

    Adolescent
    Adult
    Aged
    Case-Control Studies
    Child
    Child, Preschool
    Confidence Intervals
    Europe
    Female
    Hospitalization
    Humans
    Infant
    Infant, Newborn
    Influenza A Virus, H3N2 Subtype
    Influenza A Virus, H3N8 Subtype
    Influenza Vaccines
    Influenza, Human
    Logistic Models
    Male
    Middle Aged
    Nasopharynx
    Nose
    Reverse Transcriptase Polymerase Chain Reaction
    Seasons
    Sentinel Surveillance
    Treatment Outcome
    Vaccination
    Young Adult

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    23399425

    Citation

    Kissling, E, et al. "Low and Decreasing Vaccine Effectiveness Against Influenza A(H3) in 2011/12 Among Vaccination Target Groups in Europe: Results From the I-MOVE Multicentre Case-control Study." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 18, no. 5, 2013.
    Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5).
    Kissling, E., Valenciano, M., Larrauri, A., Oroszi, B., Cohen, J. M., Nunes, B., ... Moren, A. (2013). Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 18(5).
    Kissling E, et al. Low and Decreasing Vaccine Effectiveness Against Influenza A(H3) in 2011/12 Among Vaccination Target Groups in Europe: Results From the I-MOVE Multicentre Case-control Study. Euro Surveill. 2013 Jan 31;18(5) PubMed PMID: 23399425.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. AU - Kissling,E, AU - Valenciano,M, AU - Larrauri,A, AU - Oroszi,B, AU - Cohen,J M, AU - Nunes,B, AU - Pitigoi,D, AU - Rizzo,C, AU - Rebolledo,J, AU - Paradowska-Stankiewicz,I, AU - Jiménez-Jorge,S, AU - Horváth,J K, AU - Daviaud,I, AU - Guiomar,R, AU - Necula,G, AU - Bella,A, AU - O'Donnell,J, AU - Głuchowska,M, AU - Ciancio,B C, AU - Nicoll,A, AU - Moren,A, Y1 - 2013/01/31/ PY - 2013/2/13/entrez PY - 2013/2/13/pubmed PY - 2013/4/10/medline JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill. VL - 18 IS - 5 N2 - Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case–control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/23399425/Low_and_decreasing_vaccine_effectiveness_against_influenza_A_H3__in_2011/12_among_vaccination_target_groups_in_Europe:_results_from_the_I_MOVE_multicentre_case_control_study_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20390 DB - PRIME DP - Unbound Medicine ER -